Boehringer Ingelheim International Gmbh

Novartis Ag

Sandvik Aktiebolag

Sandoz Gmbh

Irm LLC

Krupp Widia Gmbh

Novartis Pharma Gmbh

Peter Ettmayer

Steffen Steurer

Andreas Mantoulidis

Klaus Hinterding

Peter Nussbaumer

Ioannis Sapountzis

Irene Waizenegger

Christian Klein

Nathanael Schiander Gray

Georg Dahmann

Shifeng Pan

Rainer Albert

Martin Steegmaier

Lawrence Blas Perez

Yuan Mi

Claus Ehrhardt

Nathanael S Gray

Richard Kieffer

Walter Spevak

Ulrich Reiser

Wenqi Gao

Stephan Karl Zahn

Andreas Billich

Hans Kolaska

Philipp Lehr

Wei Wang

Oliver Kraemer

Peter Sennhenn

Dieter Scholz

Hubert Gstach

Klemens Högenauer

Klaus Weigand

Sophie Lefebvre

Brigitte Charpiot

Wenqui Gao

Kenneth Richad La Montagne

Fan Yi

Federic Zecri

Max Woisetschlager

Murty Bulusu

Kenneth Richard La Montagne

Ying Fan

Frédéric Zecri

The present invention encompasses compounds of general formula (1) where in the groups Rto Rand L are defined as in claim, which are suitable for the 5 treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments. 

B-RAF kinase inhibitors

The present invention encompasses compounds of general formula (1), wherein the groups Rto Rand L are defined as in claim, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties. 

Chemical compounds

The present invention encompasses compounds of general formula (1) wherein the groups Rto Rand L are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments. 

Pyridyltriazoles

The present invention relates to new compounds of general formula (I), wherein the groups Rto R, X, X, Xand Lare defined as in claim, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof in such a treatment. 

Substituted heteroaryl inhibitors of B-RAF

The present invention encompasses compounds of general formula (1) wherein the groups Rto R, X, X, X, Land Lare defined as in claim, which are suitable for the treatment of diseases characterized by excessive or anomalous cell proliferation, and the use thereof in such a treatment. 

Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors

The present invention encompasses compounds of general formula (1), wherein the groups Rto R, X, X, X, X, X, Q, Land Lare defined as in claim, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds. 

Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases

The present invention encompasses compounds of general formula (1) wherein R, M, Land Q are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties. 

The present invention encompasses compounds of general formula (1) wherein the groups Rto R, L, Q and n are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Compounds of formula I, wherein X, a, b, R, R, R, Rand Rare as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators

An amine, which is substituted by phenyl-substituted pyrimidin; and phenyl; and a third substituent and its use as an immunoglobulin E (IgE) inhibitor.

Phenylpyrimidine amines as IgE inhibitors

The present invention relates to biphenylyl derivatives, processes for their production, their uses and pharmaceutical compositions containing them. Compounds according to the present invention are based upon the chemical formula: wherein the substituents have the values mentioned herein.

Bis-aromatic alkanols

The invention relates to compounds of formula I ##STR1## wherein the substituents have various significances. They can be prepared by conventional methods, e.g. coupling, substitution, deprotection or protection reactions. They possess interesting pharmacological properties and are thus indicated for use in the treatment of retroviral infections, particularly as HIV proteinase inhibitors.

2,4-diamino-3-hydroxycarboxylic acid derivatives

A sintered hard metal body having improved heat resistance and higher cutting performance is produced by a process including mixing together at least one hard substance, at least one binder material, and at least one of at least one complex carbide and at least one complex nitride to form a starting mixture each constituent of which is in powdered form. The at least one hard substance is selected from the group consisting of carbides, nitrides, and carbonitrides of transition metals of Groups IVB, VB and VIB of the Periodic Table of Elements, is present as at least one of a carbide, a mixed carbide, a nitride, a mixed nitride, a carbonitride, and a mixed carbonitride, and has a cubic crystal form. The at least one binder metal is selected from the group including iron, nickel and cobalt. The starting mixture is then ground and compressed into a predetermined shape, followed by sintering to melt the at least one binder metal and decompose the complex carbide and/or complex nitride to form at least one of at least one transition metal carbide and at least one transition metal nitride which grows on the surface of the at least one hard substance in powdered form and forms a diffusion inhibiting layer thereon.

Process for producing a sintered hard metal body and sintered hard metal

An improvement in a cemented carbide is disclosed. Molybdenum, tungsten and carbon are mixed and heated in a nitrogen-containing atmosphere to form a tungsten-molybdenum carbonitride (Mo, W) (C, N) having the structure of tungsten carbide. The molybdenum-tungsten carbonitride is mixed with a binder metal (and, if desired, another hard material) and sintered in a conventional manner to form a dense, substantially pore-free material which is similar in a number of properties to the more expensive tungsten carbide.

Cemented carbide

An improvement in a cemented carbide is disclosed. Molybdenum, tungsten and carbon are mixed and heated in a nitrogen containing atmosphere to form a tungsten-molybdenum carbonitride (Mo, W) (C, N) having the structure of tungsten carbide. The molybdenum-tungsten carbonitride is mixed with a binder metal (and, if desired, another hard material) and sintered in a conventional manner to form a dense, substantially pore-free material which is similar in a number of properties to the more expensive tungsten carbide.

Cemented carbide containing molybdenum tungsten carbonitride having WC

Growing community of inventors

Vienna, Austria

Peter Ettmayer